This Circular advises NHS Boards and community pharmacy contractors of the next Public Health Service (PHS) poster campaign topics which will be distributed to pharmacies.

This Circular advises NHS Boards and community pharmacy contractors that the UK-wide active Serious Shortage Protocol (SSP) for Jext® 300 micrograms/ 0.3mL (1 in 1000) solution for injection auto-injector pen

This Circular advises community pharmacy contractors that the UK-wide active Serious Shortage Protocol (SSP) for Estradot® (estradiol hemihydrate) 100 microgram patches

We are consulting on new standards on palliative and end-of-life care for community pharmacy. The consultation will be open for a four-week period from November 1 – December 1 2022.

The Chief Pharmaceutical Officer for Scotland has commissioned a review of medicines homecare services. This is being led by Banjamin Hannan, Director of Pharmacy for NHS Fife.

This Circular advises community pharmacy contractors that two of the UK-wide Serious Shortage Protocols (SSPs) for Clarithromycin antibiotic

This circular advises of changes to the Drug Tariff with respect to remuneration arrangements for the dispensing pool month of July.

Our colleagues at Scottish Government have published the following circular advising community pharmacy contractors and NHS Boards that a naloxone emergency supply service will be added to the community pharmacy Public Health Service from 30th of October 2023.

Advance payments are made to support contractor cashflow while actual payment for the prescriptions submitted is calculated.

This Circular advises community pharmacy contractors that the UK-wide active Serious Shortage Protocol (SSP) for Estradot® (estradiol hemihydrate) 100 microgram patches

As touched on in the introduction to pharmacy funding, part of a pharmacy’s income is dependent on the money made on part 7 drug tariff medicines they source and provide on prescription – this profit is often referred to as the margin

This Circular advises community pharmacy contractors that the UK-wide active Serious Shortage Protocol (SSP) for Utrogestan®

Advance payments are made to support contractor cashflow while actual payment for the prescriptions submitted is calculated.

Over the years as the pharmacy contract has changed, different service payments have been joined together into what we now call the Establishment Payment.

The Pharmaceutical Needs Weighting Payment (PNWP) makes the payment for the additional pharmaceutical needs (and associated workload) from age and deprivation characteristics of the people using the pharmacy.

The Service Efficiency Payment is for achieving a target level of electronic claiming for prescriptions submitted for pricing by Practitioner Services.

Quality and Service Development supports the operation of a service for coeliac patients and the development of a safety culture

The payments for MCR are made using one of the more complex models in our financial package and is based on the number of people registered for the service (capitation model) at the end of a given month.

Base payment of £1,000 and an activity payment from the activity payment pot of £1.308m where their activity level is above a specified minimum of 100.

A monthly fee of £3,000 will be made to the contractor named on the Board’s pharmaceutical list at the 1st day of that month for each full month the service is made available in the community pharmacy.